Eli Lilly said it is investing another $5.3 billion in a manufacturing plant in Lebanon, Indiana, to expand the supply of its highly popular weight loss drug Zepbound, diabetes treatment Mounjaro ...
New investment brings Lilly’s total commitment at LEAP Research and Innovation District in Lebanon to $9 billion, 900 new jobs. In addition to the new investment, Lilly will create another ...
Eli Lilly & Company has announced it is investing another $5.3 billion in a manufacturing plant in Lebanon, Indiana, to boost manufacturing of its highly popular weight loss drug Zepbound, diabetes ...
Yes! I want to get the latest chemistry news from C&EN in my inbox every week. ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly ...
Eli Lilly plans to invest an additional $5.3B to manufacture more of its blockbuster weight-loss and diabetes treatments at its Indiana plant, the pharma giant announced Friday. The expansion is ...
Since scoring approval two years ago for its next-generation diabetes treatment Mounjaro (tirzepatide), Eli Lilly has been playing catch up with market leader Novo Nordisk. On Friday, the ...
Faced with overwhelming demand for its diabetes treatment Mounjaro and weight-loss treatment Zepbound, Indianapolis-based drugmaker Eli Lilly and Co. said Friday morning it plans to invest another ...
Eli Lilly is investing a further $5.3 billion (€4.9 billion) in a new US manufacturing site, one of the biggest investments of its kind, to boost production of its hugely popular diabetes and ...
Pharmaceutical giant Eli Lilly opened its new Concord, NC, facility on Friday. The company has invested more than $2 billion ...
The expansion will enhance Lilly's capacity to manufacture tirzepatide, an active pharmaceutical ingredient for Zepbound and Mounjaro. Eli Lilly expects to begin making medicines in Lebanon ...